Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30895563 | 1.00 | MEN1 (0.48) | MEN1KMT2AGAATDP1ATM | |
| SCHEMBL3754005 | 0.97 | TDP1 (0.48) | MEN1KMT2AGAATDP1ATM | |
| SCHEMBL29400712 | 0.97 | TDP1 (0.48) | MEN1KMT2AGAATDP1ATM | |
| SCHEMBL9931542 | 0.97 | TDP1 (0.48) | MEN1KMT2AGAATDP1ATM | |
| SCHEMBL16076756 | 0.93 | MEN1 (0.49) | MEN1KMT2AGAATDP1ATM | |
| SCHEMBL10190377 | 0.92 | MEN1 (0.40) | MEN1KMT2AGAATDP1ATM | |
| SCHEMBL18206800 | 0.91 | CA1 (0.49) | MEN1KMT2AGAATDP1ATM | |
| SCHEMBL18206801 | 0.91 | CA1 (0.49) | MEN1KMT2AGAATDP1ATM | |
| SCHEMBL10046236 | 0.90 | MEN1 (0.38) | MEN1KMT2AGAATDP1ATM | |
| SCHEMBL15893373 | 0.89 | TDP1 (0.44) | MEN1KMT2AGAATDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9295679-B2 | Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-03-29 | — | — | US | disclosed |
| US-9295679-B2 | Prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150174143-A1 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-06-25 | — | — | US | disclosed |
| US-20150174143-A1 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-06-25 | — | — | US | disclosed |
| US-20110118219-A1 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118219-A1 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2009120565-A2 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174143-A1 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | CYP21A2, HSD17B11, CYP19A1 | MEN1 3659/4885KMT2A 3302/4885GAA 1486/4885 |
| US-20110118219-A1 | NOVEL PRODRUGS OF C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS: SYNTHESIS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | CYP21A2, HSD17B11, HSD17B1 | MEN1 3780/4885KMT2A 2850/4885GAA 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.